All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Two cases of cerebral edema, both ending in death, led Juno Therapeutics Inc. to put a clinical hold on a phase II trial of its chimeric antigen receptor (CAR) T-cell therapy, JCAR015, for the second time in five months.